| 1 |
28074333 | Rosiglitazone Metabolism in Human Liver Microsomes Using a Substrate Depletion Method. | 2017 Mar |
1 |
| 2 |
29174535 | Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human. | 2017 Dec |
1 |
| 3 |
26467040 | CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver. | 2016 Jan |
1 |
| 4 |
26581561 | Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors. | 2016 Jul |
2 |
| 5 |
26721703 | Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. | 2016 Jan |
1 |
| 6 |
27271184 | CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. | 2016 Nov |
2 |
| 7 |
23064958 | Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. | 2013 Jan |
1 |
| 8 |
23307233 | Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. | 2013 Jun |
5 |
| 9 |
23426382 | The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. | 2013 Apr |
5 |
| 10 |
22242967 | The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. | 2012 Aug |
4 |
| 11 |
22680343 | Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. | 2012 Jul |
5 |
| 12 |
21245287 | Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. | 2011 Apr |
8 |
| 13 |
21499911 | In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction. | 2011 Sep |
1 |
| 14 |
21511944 | In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. | 2011 Jul |
2 |
| 15 |
21726541 | Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. | 2011 Sep 15 |
1 |
| 16 |
19477697 | Simultaneous quantification of rosiglitazone and its two major metabolites, N-desmethyl and p-hydroxy rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. | 2009 Jul 1 |
1 |
| 17 |
19761371 | Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. | 2009 Sep |
2 |
| 18 |
18303964 | Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. | 2008 Mar |
1 |
| 19 |
19129086 | Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. | 2008 Sep |
5 |
| 20 |
16981900 | Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. | 2007 Mar |
2 |
| 21 |
17201456 | Pharmacokinetic interactions with thiazolidinediones. | 2007 |
1 |
| 22 |
17244766 | Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. | 2007 Feb |
1 |
| 23 |
16299161 | Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. | 2006 Jan |
1 |
| 24 |
16856883 | The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects. | 2006 Dec |
3 |
| 25 |
17178266 | Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. | 2006 Dec |
2 |
| 26 |
15601807 | Examination of 209 drugs for inhibition of cytochrome P450 2C8. | 2005 Jan |
1 |
| 27 |
15606443 | The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. | 2005 Jan |
4 |
| 28 |
16027405 | Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. | 2005 Aug |
1 |
| 29 |
16372821 | Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | 2005 |
2 |
| 30 |
15001966 | Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. | 2004 Mar |
1 |
| 31 |
15063342 | Simplified method for determination of rosiglitazone in human plasma. | 2004 Apr 25 |
1 |
| 32 |
15371985 | Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. | 2004 Sep |
5 |
| 33 |
15373932 | Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. | 2004 Oct |
4 |
| 34 |
10510156 | Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. | 1999 Sep |
3 |